{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:19:09Z","timestamp":1792271949429,"version":"4.4.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.dld.2017.11.013","type":"journal-article","created":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T18:30:58Z","timestamp":1511807458000},"page":"113-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7652-4236","authenticated-orcid":false,"given":"Temi","family":"Lampejo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2017.11.013_bib0005","doi-asserted-by":"crossref","first-page":"e0177195","DOI":"10.1371\/journal.pone.0177195","article-title":"The impact of HCV therapy in a high HIV\u2013HCV prevalence population: a modeling study on people who inject drugs in Ho Chi Minh City, Vietnam","volume":"12","author":"Birger","year":"2017","journal-title":"PLoS One"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2017.11.013_bib0010","article-title":"HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms","volume":"55","author":"Taylor","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.dld.2017.11.013_bib0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/09540120802017610","article-title":"Risks for HIV, HBV, and HCV infections among male injection drug users in northern Vietnam: a case-control study","volume":"21","author":"Quan","year":"2009","journal-title":"AIDS Care"},{"issue":"1","key":"10.1016\/j.dld.2017.11.013_bib0020","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/ije\/dyh019","article-title":"Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China","volume":"33","author":"Garten","year":"2004","journal-title":"Int J Epidemiol"},{"issue":"8","key":"10.1016\/j.dld.2017.11.013_bib0025","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/QAD.0b013e3281053a0c","article-title":"Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours","volume":"21","author":"Danta","year":"2007","journal-title":"AIDS"},{"issue":"11","key":"10.1016\/j.dld.2017.11.013_bib0030","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1097\/QAD.0000000000001522","article-title":"MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection","volume":"31","author":"Hoornenborg","year":"2017","journal-title":"AIDS"},{"issue":"7","key":"10.1016\/j.dld.2017.11.013_bib0035","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/hiv.12487","article-title":"Recreational drug use and chemsex among HIV-infected in-patients: a unique screening opportunity","volume":"18","author":"Elliot","year":"2017","journal-title":"HIV Med"},{"issue":"8","key":"10.1016\/j.dld.2017.11.013_bib0040","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/cid\/cir991","article-title":"Transmission of hepatitis C virus infection through tattooing and piercing: a critical review","volume":"54","author":"Tohme","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.dld.2017.11.013_bib0045","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/eurpub\/ckp178","article-title":"Knowledge, attitudes and risk of HIV, HBV and HCV infections in hairdressers of Palermo city (South Italy)","volume":"20","author":"Amodio","year":"2010","journal-title":"Eur J Public Health"},{"issue":"3","key":"10.1016\/j.dld.2017.11.013_bib0050","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jhep.2008.04.010","article-title":"Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients","volume":"49","author":"Shores","year":"2008","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.dld.2017.11.013_bib0055","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/gut.2010.217166","article-title":"Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men","volume":"60","author":"Thomson","year":"2011","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.dld.2017.11.013_bib0060","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/QAD.0b013e328343443b","article-title":"Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference","volume":"25","author":"Panel","year":"2011","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.dld.2017.11.013_bib0065","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jhep.2013.04.029","article-title":"Impaired CD4+ T cell stimulation of NK cell anti-fibrotic activity may contribute to accelerated liver fibrosis progression in HIV\/HCV patients","volume":"59","author":"Gl\u00e4ssner","year":"2013","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.dld.2017.11.013_bib0070","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s11904-013-0169-5","article-title":"Update on HIV\/HCV coinfection","volume":"10","author":"Soriano","year":"2013","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"9772","key":"10.1016\/j.dld.2017.11.013_bib0075","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/S0140-6736(10)62001-6","article-title":"Increasing burden of liver disease in patients with HIV infection","volume":"377","author":"Joshi","year":"2011","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.dld.2017.11.013_bib0080","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1086\/432618","article-title":"Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis","volume":"41","author":"Miller","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.dld.2017.11.013_bib0085","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.dld.2017.11.013_bib0090","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2009.09.019","article-title":"Effective treatment of injecting drug users with recently acquired hepatitis C virus infection","volume":"138","author":"Dore","year":"2010","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.dld.2017.11.013_bib0095","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1089\/apc.2011.0106","article-title":"Acute hepatitis C virus in an HIV clinic: a screening strategy, risk factors, and perception of risk","volume":"25","author":"Taylor","year":"2011","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.dld.2017.11.013_bib0100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coviro.2017.03.017","article-title":"Direct-acting antivirals: the endgame for hepatitis C?","volume":"24","author":"D\u2019Ambrosio","year":"2017","journal-title":"Curr Opin Virol"},{"issue":"1","key":"10.1016\/j.dld.2017.11.013_bib0105","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL recommendations on treatment of hepatitis C","volume":"66","year":"2017","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.dld.2017.11.013_bib0110","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/QAD.0000000000001465","article-title":"Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection","volume":"31","author":"Montes","year":"2017","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.dld.2017.11.013_bib0115","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","author":"Chung","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2017.11.013_bib0120","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jhep.2004.04.002","article-title":"Interferon-a for hepatitis C: antiviral or immunotherapy?","volume":"40","author":"Diepolder","year":"2004","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.dld.2017.11.013_bib0125","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1053\/jhep.2003.50194","article-title":"Detection of functionally altered hepatitis C virus-specific CD4\u2009T cells in acute and chronic hepatitis C","volume":"37","author":"Ulsenheimer","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2017.11.013_bib0130","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.antiviral.2014.11.009","article-title":"T cell responses in hepatitis C virus infection: historical overview and goals for future research","volume":"114","author":"Holz","year":"2015","journal-title":"Antiviral Res"},{"issue":"1","key":"10.1016\/j.dld.2017.11.013_bib0135","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.gastro.2003.10.076","article-title":"Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A","volume":"126","author":"Duong","year":"2004","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.dld.2017.11.013_bib0140","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1006\/viro.1997.8493","article-title":"Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein","volume":"230","author":"Gale Michael","year":"1997","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.dld.2017.11.013_bib0145","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s15010-015-0856-9","article-title":"Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcome","volume":"44","author":"Boesecke","year":"2016","journal-title":"Infection"},{"issue":"5","key":"10.1016\/j.dld.2017.11.013_bib0150","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1086\/596770","article-title":"Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C","volume":"48","author":"Matthews","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.dld.2017.11.013_bib0155","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jhep.2015.12.004","article-title":"Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients","volume":"64","author":"Hullegie","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2017.11.013_bib0160","doi-asserted-by":"crossref","DOI":"10.3851\/IMP3143","article-title":"Telaprevir-containing triple therapy in acute HCV coinfection: the CHAT study","author":"Boesecke","year":"2017","journal-title":"Antivir Ther"},{"issue":"1","key":"10.1016\/j.dld.2017.11.013_bib0165","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/imr.12066","article-title":"CD4+ T-cell depletion in HIV infection: mechanisms of immunological failure","volume":"254","author":"Okoye","year":"2013","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1016\/j.dld.2017.11.013_bib0170","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S2352-3018(15)00006-5","article-title":"CD4\/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study","volume":"2","author":"Mussini","year":"2015","journal-title":"Lancet HIV"},{"issue":"1","key":"10.1016\/j.dld.2017.11.013_bib0175","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/QAI.0000000000001013","article-title":"Brief report: enhanced normalization of CD4\/CD8 ratio with earlier antiretroviral therapy at primary HIV infection","volume":"73","author":"Thornhill","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"10.1016\/j.dld.2017.11.013_bib0180","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1310\/hct1404-127","article-title":"Sustained virological response and baseline predictors in HIV\u2013HCV coinfected patients retreated with pegylated interferon and ribavirin after failing a previous interferon-based therapy: systematic review and meta-analysis","volume":"14","author":"Basso","year":"2013","journal-title":"HIV Clin Trials"},{"issue":"S4","key":"10.1016\/j.dld.2017.11.013_bib0185","doi-asserted-by":"crossref","first-page":"s2","DOI":"10.1111\/hiv.12426","article-title":"British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015","volume":"17","author":"Churchill","year":"2016","journal-title":"HIV Med"},{"key":"10.1016\/j.dld.2017.11.013_bib0190","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/cid\/cix025","article-title":"Sofosbuvir plus ribavirin without interferon for treatment of acute hepatitis c virus infection in HIV-1-Infected individuals: SWIFT-C","volume":"64","author":"Naggie","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.dld.2017.11.013_bib0195","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1002\/hep.28844","article-title":"Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: the DARE-C II study","volume":"64","author":"Martinello","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2017.11.013_bib0200","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1080\/15284336.2017.1280594","article-title":"Sofosbuvir in the treatment of early HCV infection in HIV-infected men","volume":"18","author":"El Sayed","year":"2017","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.dld.2017.11.013_bib0205","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S2468-1253(17)30003-1","article-title":"Ledipasvir\u2013sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial","volume":"2","author":"Rockstroh","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7053","key":"10.1016\/j.dld.2017.11.013_bib0210","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","article-title":"Mechanism of action of interferon and ribavirin in treatment of hepatitis C","volume":"436","author":"Feld","year":"2005","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.dld.2017.11.013_bib0215","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/liv.13212","article-title":"Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection","volume":"37","author":"Feld","year":"2017","journal-title":"Liver Int"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2017.11.013_bib0220","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1478-3231.2011.02711.x","article-title":"The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C","volume":"32","author":"Clark","year":"2012","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.dld.2017.11.013_bib0225","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jhep.2015.09.009","article-title":"Ideal oral combinations to eradicate HCV: the role of ribavirin","volume":"64","author":"H\u00e9zode","year":"2016","journal-title":"J Hepatol"},{"issue":"9973","key":"10.1016\/j.dld.2017.11.013_bib0230","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0140-6736(14)62401-6","article-title":"Lancet seminar \u2014 hepatitis C","volume":"385","author":"Webster","year":"2015","journal-title":"Lancet (London England)"},{"issue":"1","key":"10.1016\/j.dld.2017.11.013_bib0235","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jhep.2017.02.012","article-title":"Efficacy and safety of direct-acting antiviral regimens in HIV\/HCV-co-infected patients \u2014 French ANRS CO13 HEPAVIH cohort","volume":"67","author":"Piroth","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2017.11.013_bib0240","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijid.2017.07.001","article-title":"HCV-infected and HIV\/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?","volume":"62","author":"Bruno","year":"2017","journal-title":"Int J Infect Dis"},{"issue":"5","key":"10.1016\/j.dld.2017.11.013_bib0245","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/QAI.0000000000000516","article-title":"Sofosbuvir for chronic hepatitis C virus infection genotype 1\u20134 in patients coinfected with HIV","volume":"68","author":"Rodriguez-Torres","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2017.11.013_bib0250","series-title":"Liverpool HIV interactions","year":"2017"},{"issue":"7","key":"10.1016\/j.dld.2017.11.013_bib0255","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/cid\/civ1222","article-title":"How generalizable are the results from trials of direct antiviral agents to people coinfected with HIV\/HCV in the real world?","volume":"62","author":"Saeed","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.dld.2017.11.013_bib0260","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1473-3099(13)70059-8","article-title":"Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial","volume":"13","author":"Deterding","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.dld.2017.11.013_bib0265","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/COH.0b013e32834b87de","article-title":"HIV and hepatitis C co-infection: acute HCV therapy","volume":"6","author":"Boesecke","year":"2011","journal-title":"Curr Opin HIV AIDS"},{"issue":"11","key":"10.1016\/j.dld.2017.11.013_bib0270","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/jvh.12272","article-title":"Peginterferon-alfa mono-therapy in the treatment of acute hepatitis C in HIV-infection","volume":"21","author":"Boesecke","year":"2014","journal-title":"J Viral Hepat"},{"issue":"5","key":"10.1016\/j.dld.2017.11.013_bib0275","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2016.12.019","article-title":"Increased peripheral CD4+ regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C","volume":"66","author":"Langhans","year":"2017","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.dld.2017.11.013_bib0280","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jhep.2017.03.036","article-title":"In HIV\/HCV co-infected patients T regulatory and myeloid-derived suppressor cells persist after successful treatment with directly acting antivirals","volume":"67","author":"Tumino","year":"2017","journal-title":"J Hepatol"},{"issue":"19","key":"10.1016\/j.dld.2017.11.013_bib0285","doi-asserted-by":"crossref","first-page":"10429","DOI":"10.1128\/JVI.01094-10","article-title":"Comparison of immune restoration in early versus late alpha interferon therapy against hepatitis C virus","volume":"84","author":"Abdel-Hakeem","year":"2010","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.dld.2017.11.013_bib0290","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/jvh.12707","article-title":"HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C","volume":"24","author":"Steininger","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.dld.2017.11.013_bib0295","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/COH.0b013e32833a0d3a","article-title":"Role of acute and early HIV infection in the sexual transmission of HIV","volume":"5","author":"Miller","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"issue":"7","key":"10.1016\/j.dld.2017.11.013_bib0300","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1086\/512088","article-title":"High rates of forward transmission events after acute\/early HIV-1 infection","volume":"195","author":"Brenner","year":"2007","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.dld.2017.11.013_bib0305","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciw075","article-title":"Can hepatitis C virus (HCV) direct-Acting antiviral treatment as prevention reverse the HCV epidemic among men who have sex with men in the United Kingdom? Epidemiological and modeling insights","volume":"62","author":"Martin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2017.11.013_bib0310","article-title":"Substantial decline in acute hcv infections among dutch HIV+MSM after daa roll out","author":"Boerekamps","year":"2017","journal-title":"CROI 2017"},{"issue":"2","key":"10.1016\/j.dld.2017.11.013_bib0315","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/hep.21043","article-title":"Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study","volume":"43","author":"Wiegand","year":"2006","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.dld.2017.11.013_bib0320","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/cid\/cit799","article-title":"Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men","volume":"58","author":"Fierer","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2017.11.013_bib0325","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/jvh.12654","article-title":"Sofosbuvir plus ribavirin in treatment-na\u00efve patients with chronic hepatitis C virus genotype 1 or 3 infection in India","volume":"24","author":"Shah","year":"2017","journal-title":"J Viral Hepat"},{"issue":"1","key":"10.1016\/j.dld.2017.11.013_bib0330","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.qai.0000174930.64145.a9","article-title":"Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin","volume":"40","author":"Gilleece","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"10.1016\/j.dld.2017.11.013_bib0335","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1473-3099(16)30408-X","article-title":"Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study","volume":"17","author":"Deterding","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.dld.2017.11.013_bib0340","first-page":"S14","article-title":"Sofosbuvir and ledipasvir versus sofosbuvir and simeprevir for acute hepatitis C: A RCT: SLAM C study","volume":"10","author":"Basu","year":"2016","journal-title":"Hepatol Int"},{"issue":"8","key":"10.1016\/j.dld.2017.11.013_bib0345","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa1501315","article-title":"Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Naggie","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.dld.2017.11.013_bib0350","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2010.07.005","article-title":"A polymorphism near IL28 B is associated with spontaneous clearance of acute hepatitis C virus and jaundice","volume":"139","author":"Tillmann","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.11.013_bib0355","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw235","article-title":"Estimating the time to diagnosis and the chance of spontaneous clearance during acute hepatitis C in human immunodeficiency virus-infected individuals","volume":"4","author":"Ragonnet","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"21","key":"10.1016\/j.dld.2017.11.013_bib0360","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.dld.2017.11.013_bib0365","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.dld.2017.11.013_bib0370","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/cid\/ciw163","article-title":"12 weeks of daclatasvir in combination with sofosbuvir for HIV\u2013HCV coinfection (ALLY-2 study): efficacy and safety by HIV combination antiretroviral regimens","volume":"62","author":"Luetkemeyer","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2017.11.013_bib0375","first-page":"1","article-title":"Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy","author":"Banerjee","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2017.11.013_bib0380","article-title":"Sofosbuvir\/velpatasvir in patients with hepatitis C virus genotypes 1\u20136 and compensated cirrhosis or advanced fibrosis","author":"Asselah","year":"2017","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.dld.2017.11.013_bib0385","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2014.7734","article-title":"Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection","volume":"312","author":"Sulkowski","year":"2014","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.dld.2017.11.013_bib0390","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jcv.2013.09.022","article-title":"No detection of the NS5\u00e0B S282T mutation in treatment-na\u2009ve genotype 1 HCV\/HIV-1 coinfected patients using deep sequencing","volume":"58","author":"Franco","year":"2013","journal-title":"J Clin Virol"},{"issue":"2","key":"10.1016\/j.dld.2017.11.013_bib0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2016.09.018","article-title":"Use of whole genome sequencing in the Dutch Acute HCV in HIV study: focus on transmitted antiviral resistance","volume":"23","author":"Christiansen","year":"2017","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1016\/j.dld.2017.11.013_bib0400","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.24262","article-title":"Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus","volume":"53","author":"Pawlotsky","year":"2011","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.dld.2017.11.013_bib0405","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir","volume":"151","author":"Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.11.013_bib0410","doi-asserted-by":"crossref","DOI":"10.3851\/IMP3181","article-title":"Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir","author":"Wyles","year":"2017","journal-title":"Antivir Ther"},{"issue":"19","key":"10.1016\/j.dld.2017.11.013_bib0415","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMp1201796","article-title":"HIV-HBV coinfection?a global challenge","volume":"366","author":"Kourtis","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.dld.2017.11.013_bib0420","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1111\/jgh.13771","article-title":"Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals","volume":"32","author":"Yeh","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.dld.2017.11.013_bib0425","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/apt.14177","article-title":"No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort","volume":"46","author":"M\u00fccke","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dld.2017.11.013_bib0430","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/hep.29109","article-title":"Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis","volume":"66","author":"Chen","year":"2017","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.dld.2017.11.013_bib0435","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s11901-010-0060-4","article-title":"Current concepts of HBV\/HCV coinfection: coexistence, but not necessarily in harmony","volume":"9","author":"Jamma","year":"2010","journal-title":"Curr Hepat Rep"},{"issue":"6","key":"10.1016\/j.dld.2017.11.013_bib0440","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0168-8278(02)00296-9","article-title":"Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein","volume":"37","author":"Sch\u00fcttler","year":"2002","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2017.11.013_bib0445","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1074\/jbc.M204241200","article-title":"Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein","volume":"278","author":"Chen","year":"2003","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.dld.2017.11.013_bib0450","first-page":"338","article-title":"Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights","volume":"13","author":"G\u00f6tte","year":"2016","journal-title":"Nat Publ Gr"},{"issue":"1","key":"10.1016\/j.dld.2017.11.013_bib0455","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"EASL","year":"2012","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.dld.2017.11.013_bib0460","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/hiv.12501","article-title":"High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV\/HCV coinfected people who use drugs","volume":"18","author":"Soc\u00edas","year":"2017","journal-title":"HIV Med"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865817313099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865817313099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T02:56:37Z","timestamp":1660013797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865817313099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1590865817313099"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2017.11.013","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2017.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}